类风湿关节炎中持续性克隆性T细胞大颗粒淋巴细胞扩增的患病率与特征:529例患者的综合分析
研究纳入2013年11月至2015年8月期间529例类风湿关节炎(RA)患者,用八色流式细胞术筛查异常T细胞大颗粒淋巴细胞(T-LGL)群,并用T细胞受体分子分析确认。19例检出克隆性T-LGL扩增,患病率3.6%;克隆持续存在且与TNF阻断剂暴露时长显著相关(P=0.01)。
要点
- 529例RA患者中克隆性T-LGL扩增患病率为3.6%(19例)。
- 多数患者T-LGL克隆随时间保持稳定。
- 克隆性T-LGL扩增与TNF阻断剂暴露时长显著相关(P=0.01)。
核心结论
- 长期暴露于TNF阻断剂的RA患者发生LGL克隆性扩增的风险更高。
- 该发现可能促使临床医生对已知存在T细胞异常的RA患者避免使用这类药物。
研究设计与样本
- 2013年11月至2015年8月期间招募529例RA患者。
- 采用八色流式细胞术(FACS)筛查LGL异常T细胞群。
- 对FACS提示异常的患者用T细胞受体分子分析确认诊断。
- 通过电子病历确定危险因素,并对克隆性群体患者前瞻性随访最长4年。
主要发现
- 患者中位年龄61岁,女性占74%,RA中位病程12年。
- 28关节疾病活动度评分中位值2.8,69.9%患者曾接受生物制剂改善病情抗风湿药治疗。
- 19例检出克隆性T-LGL扩增,患病率3.6%。
- 多数患者T-LGL细胞克隆随时间保持恒定。
- T-LGL克隆与TNF阻断剂暴露时长显著相关(P=0.01),未检出其他危险因素。
关键数值与推荐
- 克隆性T-LGL扩增患病率为3.6%(19/529)。
- T-LGL克隆与TNF阻断剂暴露时长的关联P=0.01。
临床怎么用
- 作者认为,该发现可能促使临床医生对已知存在T细胞异常的RA患者避免使用TNF阻断剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Up to one-third of patients with T cell large granular lymphocyte (T-LGL) leukemia display symptoms of rheumatoid arthritis (RA). In Crohn's disease and psoriasis, treatment with tumor necrosis factor (TNF) inhibitors is associated with hepatosplenic γδ T cell lymphoma and with clonal expansion of γδ T cells, respectively. This study was undertaken to determine the prevalence of clonal T-LGL cells in patients with RA and define risk factors for this rare hematologic malignancy. METHODS: A total of 529 RA patients were recruited between November 2013 and August 2015. Eight-color flow cytometry (fluorescence-activated cell sorting [FACS]) was performed to screen for aberrant T cell populations of LGLs. Molecular analysis of the T cell receptor was used to confirm the diagnosis in patients with suggestive FACS findings. Electronic patient files were used to determine risk factors. Patients with clonal populations were monitored prospectively for up to 4 years. RESULTS: The median patient age was 61 years, and 74% were female. The median duration of RA was 12 years. The median Disease Activity Score in 28 joints was 2.8, and 69.9% of patients had ever been treated with biologic disease-modifying antirheumatic drugs. We identified clonal T-LGL expansions in 19 patients, equaling a prevalence of 3.6%. The T-LGL cell clone was constant over time in most patients and was significantly associated with the duration of the exposure to TNF-blocking agents (P = 0.01). No other risk factors could be detected. CONCLUSION: RA patients with long-term exposure to TNF-blocking agents were at a greater risk of developing clonal expansions of LGLs. This finding may prompt clinicians to refrain from using these substances in RA patients with known T cell aberrations.
引用
- Schwaneck EC, Renner R, Junker L, et al. Prevalence and Characteristics of Persistent Clonal T Cell Large Granular Lymphocyte Expansions in Rheumatoid Arthritis: A Comprehensive Analysis of 529 Patients. Arthritis Rheumatol. 2018. PMID: 29938921. doi:10.1002/art.40654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。